UK-based, Dxcover (previously Clinspec Diagnostics) is a clinical-stage diagnostics company. The startup has developed a liquid biopsy platform - powered by “attenuated total reflectance, fourier transform infrared spectroscopy” “of pan-omic biomarkers” - which analyzes patient blood samples (with the help of AI) to detect the presence (or absence) of cancer. It generates compelling clinical data with high accuracy detection (80-90%) of Stage I & II brain tumors, particularly Glioblastoma Multiforme (the most aggressive type). The firm has also published data with “exceptional potential” on detecting pancreatic cancer as well as 6 other types (lung, colon, breast, prostate, ovarian & kidney) (the 8-types combined, account for 65% of the global cancer burden). Various patents have already...

The global warehouse automation market was worth $19bn in 2021 & predicted to grow to $65bn by 2030. Large warehouses are driving this growth, but what about small & medium-sized ones? turns out, >10% of them are able to adopt robotic automation due to issues of high cost, complexity & long lead times. That’s where UK-based Phinxt (pronounced fin-ext) wants to step in, as the startup aims to allow 90% of SMEs to adopt robotics, by providing a cloud-based “orchestration” platform to make a variety of robots work together (e.g. integrating an AMR with a robotic picking arm). Phinxt wants to differentiate itself from e.g. Wise Robotics (UK) (€n.a.) or Waku Robotics (DE) (€2.5m) via...